Supawan Jamnongsong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Supawan Jamnongsong has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chamras Promptmas
Department of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, Thailand
1 shared publication Chanettee Jamyuang
Siriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, THAILAND
1 shared publication- Eric Wing-Fai Lam
Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK
1 shared publication - Kriengkrai Phongkitkarun
Siriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Maliwan Kamkaew
Siriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Porncheera Chusorn
Siriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 5 August 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 202, 119821
PARP inhibition induces a redox-dependent dormant reservoir vulnerable to disulfiram in high-grade serous ovarian cancer
- 5 August 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 202, 119821
Open AccessPARP inhibition induces a redox-dependent dormant reservoir vulnerable to disulfiram in high-grade serous ovarian cancer
- 30 June 2025
- Published by The Company of Biologists in Journal of Cell Science
Chemically tunable FOXM1-D sensor revealed FOXM1 direct influence on cell cycle
Forkhead box protein M1 (FOXM1) is a transcription factor required for the G2/M transition and is frequently upregulated in cancers, promoting tumor progression and therapy resistance. However, its dynamic regulation throughout the cell cycle remains unclear. We developed a tunable FOXM1-DHFR (FOXM1-D) sensor in non-malignant MCF10A cells, enabling real-time monitoring and manipulation of FOXM1 levels. Using trimethoprim (TMP) to stabilize FOXM1-D, we quantified its production, degradation, and nuclear translocation during G1 and G2 phases. Overexpression of FOXM1-D accelerated cell division in G1 and S phases but did not affect G2-synchronized cells. Notably, 70%-90% of FOXM1-D overexpressing cells were arrested after the first division, whereas those with timely degradation allowed a second division. Sustained FOXM1-D overexpression induced cell cycle arrest in daughter cells, highlighting the role of FOXM1 kinetics in determining cell fate. Sustained FOXM1-D upregulates p21, triggering G1 arrest. Thus, targeting FOXM1 exploits its dual capacity to induce oncogene-induced senescence (OIS) or suppress mitotic entry. Our study provides a basis for precision therapies that align interventions with FOXM1 kinetics to improve outcomes in FOXM1-driven tumors.
- 30 June 2025
- Published by The Company of Biologists in Journal of Cell Science
Chemically tunable FOXM1-D sensor revealed FOXM1 direct influence on cell cycle
Forkhead box protein M1 (FOXM1) is a transcription factor required for the G2/M transition and is frequently upregulated in cancers, promoting tumor progression and therapy resistance. However, its dynamic regulation throughout the cell cycle remains unclear. We developed a tunable FOXM1-DHFR (FOXM1-D) sensor in non-malignant MCF10A cells, enabling real-time monitoring and manipulation of FOXM1 levels. Using trimethoprim (TMP) to stabilize FOXM1-D, we quantified its production, degradation, and nuclear translocation during G1 and G2 phases. Overexpression of FOXM1-D accelerated cell division in G1 and S phases but did not affect G2-synchronized cells. Notably, 70%-90% of FOXM1-D overexpressing cells were arrested after the first division, whereas those with timely degradation allowed a second division. Sustained FOXM1-D overexpression induced cell cycle arrest in daughter cells, highlighting the role of FOXM1 kinetics in determining cell fate. Sustained FOXM1-D upregulates p21, triggering G1 arrest. Thus, targeting FOXM1 exploits its dual capacity to induce oncogene-induced senescence (OIS) or suppress mitotic entry. Our study provides a basis for precision therapies that align interventions with FOXM1 kinetics to improve outcomes in FOXM1-driven tumors.